Supernus Pharmaceuticals (SUPN) Net Equity Issued and Repurchased (2011 - 2026)

Supernus Pharmaceuticals has reported Net Equity Issued and Repurchased for 16 years, with the latest figure at $4.1 million in Q2 2026.

• Net Equity Issued and Repurchased for Q2 2026 came in at $4.1 million, up 25.85% year-over-year; the trailing twelve-month figure through Jun 2026 was $50.1 million (up 219.93% YoY), and the FY2025 annual result was $37.6 million, up 152.32% from the prior year.
• Net Equity Issued and Repurchased declined to $4.1 million in Q2 2026, from $13.7 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $23.7 million in Q3 2025 and troughed at $740000.0 in Q3 2023.
• A 5-year average of $5.0 million and a median of $2.9 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The widest annual swing landed in 2022, when Net Equity Issued and Repurchased jumped 1131.87%; it then plunged 88.54% in 2023.
• A 5-year view of Net Equity Issued and Repurchased shows it stood at $2.8 million in 2022, then tumbled by 61.4% to $1.1 million in 2023, then surged by 529.76% to $6.9 million in 2024, then advanced by 24.43% to $8.6 million in 2025, then sank by 51.82% to $4.1 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $4.1 million in Q2 2026, $13.7 million in Q1 2026, and $8.6 million in Q4 2025.